Literature DB >> 19365051

Propriospinal myoclonus revisited: Clinical, neurophysiologic, and neuroradiologic findings.

E Roze1, P Bounolleau, D Ducreux, V Cochen, S Leu-Semenescu, Y Beaugendre, M C Lavallard-Rousseau, A Blancher, F Bourdain, P Dupont, L Carluer, L Verdure, M Vidailhet, E Apartis.   

Abstract

OBJECTIVE: The literature on propriospinal myoclonus (PSM) is poor and there are no systematic reviews of the subject. We sought to clarify the spectrum of PSM.
METHODS: We first prospectively investigated all patients seen in our movement disorders clinic with a firm diagnosis of PSM between 2002 and 2007. All had a standardized interview, detailed clinical examination, laboratory investigations, comprehensive neurophysiologic examination, and spinal cord MRI, including diffusion tensor imaging with fiber tracking (DTI-FT). We also collected drug responses. Finally, we conducted a systematic review of the literature.
RESULTS: We enrolled 10 patients meeting the strict criteria for PSM, and also analyzed data on 50 patients from 26 previous reports. PSM occurred predominantly in male and middle-aged patients. The typical clinical picture consisted of myoclonic jerks consistently involving abdominal wall muscles, which worsen in the lying position. A premonitory sensation preceding the jerks and wake-sleep transition phase worsening were frequent. Most patients had a myoclonic generator at the thoracic level, with a myoclonus duration between 200 msec and 2 s. An underlying cause was infrequently found. DTI-FT detected cord abnormalities all of our patients.
CONCLUSION: The clinico-physiologic spectrum of propriospinal myoclonus (PSM) is homogenous. Involvement of the abdominal wall muscles, worsening in the lying position, premonitory sensation, and wake-sleep transition phase worsening are helpful clinical clues. Diffusion tensor imaging with fiber tracking appears more sensitive than conventional MRI for detecting associated microstructural abnormalities of the spinal cord. Symptomatic treatment of PSM is not straightforward, and clonazepam is reported to be the most effective drug. Zonisamide may be an interesting option.

Entities:  

Mesh:

Year:  2009        PMID: 19365051     DOI: 10.1212/WNL.0b013e3181a0fd50

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

Review 1.  An update and review of the treatment of myoclonus.

Authors:  Kelly Mills; Zoltan Mari
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

2.  Sleep and Epilepsy: Strange Bedfellows No More.

Authors:  Erik K St Louis
Journal:  Minerva Pneumol       Date:  2011-09

3.  Spinal myoclonus in a patient with hepatic encephalopathy.

Authors:  Seung-Hee Na; Hyung-Eun Park; Joong-Seok Kim
Journal:  Neurol Sci       Date:  2014-09-12       Impact factor: 3.307

4.  A restless abdomen and propriospinal myoclonus like at sleep onset: an unusual overlap syndrome.

Authors:  Simone Baiardi; Chiara La Morgia; Susanna Mondini; Fabio Cirignotta
Journal:  BMJ Case Rep       Date:  2015-03-27

Review 5.  Classification of sleep disorders.

Authors:  Michael J Thorpy
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

6.  Propriospinal myoclonus: is it always psychogenic?

Authors:  Rajesh Verma; Heramba Narayan Praharaj; Tushar Premraj Raut; Dheeraj Rai
Journal:  BMJ Case Rep       Date:  2013-07-29

7.  Video electroencephalogram combined with electromyography in the diagnosis of hyperkinetic movement disorders with an unknown cause.

Authors:  Jianhua Chen; Xiangqin Zhou; Qiang Lu; Liri Jin; Yan Huang
Journal:  Neurol Sci       Date:  2021-01-18       Impact factor: 3.307

Review 8.  The clinical approach to movement disorders.

Authors:  Wilson F Abdo; Bart P C van de Warrenburg; David J Burn; Niall P Quinn; Bastiaan R Bloem
Journal:  Nat Rev Neurol       Date:  2010-01       Impact factor: 42.937

Review 9.  Physiology-Based Treatment of Myoclonus.

Authors:  Ashley B Pena; John N Caviness
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 10.  Treatment of myoclonus.

Authors:  John N Caviness
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.